The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice
The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice
复制标题
DOI：
10.1016/j.taap.2007.03.031
复制
发表时间：
2007-07-15
影响因子：
3.8
通讯作者：
Aruoma, Okezie I.
中科院分区：
文献类型：
--
作者：
Hirose, Aya;Sato, Eri;Aruoma, Okezie I.
顺铂(顺铂或顺铂)(一种广泛使用的含铂抗癌药物)在化疗期间对患者有肾毒性，耐受率低。活性己糖相关化合物(AHCC)是担子菌的提取物，因其营养和纤维含量以及增强和优化免疫系统能力而被作为癌症患者的补充剂出售。在荷瘤的BALB/CA小鼠中，根据其改善顺铂引起的体重减轻、厌食、肾毒性和造血毒性的能力，评估了AHCC减轻顺铂副作用的可能性。虽然顺铂(8 mg/kg体重)减小了实体瘤的大小和重量，但补充AHCC显著增强了顺铂诱导的抗肿瘤作用(p
Cisplatin (cis-diaminedichloroplatinum (11) or CDDP) (a widely used platinum-containing anticancer drug) is nephrotoxic and has a low percentage of tolerance in patients during chemotherapy. The active hexose correlated compound (AHCC) is an extract of Basidiomycotina marketed as a supplement for cancer patients due to its nutrients and fibre content and its ability to strengthen and optimize the capacity of the immune system. The possibility that AHCC could reduce the side effects of cisplatin was assessed in the tumor-bearing BALB/cA mice on the basis of the ability to ameliorate the cisplatin-induced body weight loss, anorexia, nephrotoxicity and hematopoietic toxicity. Although cisplatin (8 mg/kg body weight) reduced the size and weight of the solid tumors, supplementation with AHCC significantly enhanced cisplatin-induced antitumor effect in both the size (p